MedKoo Cat#: 318452 | Name: Pantoprazole Sodium
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Pantoprazole Sodium is a gastic proton pump inhibitor. It suppresses gastric acid secretion by blocking acid (proton) pump within gastric parietal cells.

Chemical Structure

Pantoprazole Sodium
Pantoprazole Sodium
CAS#138786-67-1

Theoretical Analysis

MedKoo Cat#: 318452

Name: Pantoprazole Sodium

CAS#: 138786-67-1

Chemical Formula: C16H14F2N3NaO4S

Exact Mass:

Molecular Weight: 405.35

Elemental Analysis: C, 47.41; H, 3.48; F, 9.37; N, 10.37; Na, 5.67; O, 15.79; S, 7.91

Price and Availability

Size Price Availability Quantity
1g USD 300.00 2 Weeks
5g USD 750.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Pantoprazole Sodium; Pantoloc; Controloc; Pantecta; Zurcal; Protonix; SK and F 96022; SK and F-96022; SKF-96022;
IUPAC/Chemical Name
sodium;5-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]benzimidazol-1-ide
InChi Key
YNWDKZIIWCEDEE-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H14F2N3O4S.Na/c1-23-13-5-6-19-12(14(13)24-2)8-26(22)16-20-10-4-3-9(25-15(17)18)7-11(10)21-16;/h3-7,15H,8H2,1-2H3;/q-1;+1
SMILES Code
COC1=C(C(=NC=C1)CS(=O)C2=NC3=C([N-]2)C=CC(=C3)OC(F)F)OC.[Na+]
Appearance
Solid powder
Purity
>95% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Biological target:
Pantoprazole sodium (BY10232 sodium) is an orally active and potent proton pump inhibitor (PPI).
In vitro activity:
The present study investigated the effects of pantoprazole (PPZ) treatment and PKM2 transfection on human gastric adenocarcinoma SGC-7901 cells in vitro. The present study revealed that PPZ inhibited the proliferation of tumor cells, induced apoptosis and downregulated the expression of PKM2, which contributes to the current understanding of the functional association between PPZ and PKM2. Reference: Oncol Lett. 2016 Jan;11(1):717-722. https://pubmed.ncbi.nlm.nih.gov/26870273/
In vivo activity:
Pantoprazole (0.3-3 mg/kg, p.o.) as well as omeprazole (1-10 mg/kg, p.o.) and lansoprazole (1-10 mg/kg, p.o.) dose-dependently decreased both basal acid secretion in pylorus-ligated rats and the stimulated acid secretion induced by mepirizole in acute fistula rats, and the effects of pantoprazole were more potent than those of omeprazole and lansoprazole, the ED50 values for the stimulated acid secretion being 0.8, 2.0 and 1.2 mg/kg, respectively. Reference: J Gastroenterol Hepatol. 1999 Mar;14(3):251-7. https://pubmed.ncbi.nlm.nih.gov/10197495/
Solvent mg/mL mM
Solubility
DMSO 90.5 223.26
Ethanol 81.0 199.83
Water 42.4 104.66
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 405.35 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Zeng X, Liu L, Zheng M, Sun H, Xiao J, Lu T, Huang G, Chen P, Zhang J, Zhu F, Li H, Duan Q. Pantoprazole, an FDA-approved proton-pump inhibitor, suppresses colorectal cancer growth by targeting T-cell-originated protein kinase. Oncotarget. 2016 Apr 19;7(16):22460-73. doi: 10.18632/oncotarget.7984. PMID: 26967058; PMCID: PMC5008373. 2. Shen Y, Chen M, Huang S, Zou X. Pantoprazole inhibits human gastric adenocarcinoma SGC-7901 cells by downregulating the expression of pyruvate kinase M2. Oncol Lett. 2016 Jan;11(1):717-722. doi: 10.3892/ol.2015.3912. Epub 2015 Nov 13. PMID: 26870273; PMCID: PMC4727057. 3. Histing T, Stenger D, Scheuer C, Metzger W, Garcia P, Holstein JH, Klein M, Pohlemann T, Menger MD. Pantoprazole, a proton pump inhibitor, delays fracture healing in mice. Calcif Tissue Int. 2012 Jun;90(6):507-14. doi: 10.1007/s00223-012-9601-x. Epub 2012 Apr 24. PMID: 22527206. 4. Takeuchi K, Konaka A, Nishijima M, Kato S, Yasuhiro T. Effects of pantoprazole, a novel H+/K+-ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: a comparative study with omeprazole and lansoprazole. J Gastroenterol Hepatol. 1999 Mar;14(3):251-7. doi: 10.1046/j.1440-1746.1999.01843.x. PMID: 10197495.
In vitro protocol:
1. Zeng X, Liu L, Zheng M, Sun H, Xiao J, Lu T, Huang G, Chen P, Zhang J, Zhu F, Li H, Duan Q. Pantoprazole, an FDA-approved proton-pump inhibitor, suppresses colorectal cancer growth by targeting T-cell-originated protein kinase. Oncotarget. 2016 Apr 19;7(16):22460-73. doi: 10.18632/oncotarget.7984. PMID: 26967058; PMCID: PMC5008373. 2. Shen Y, Chen M, Huang S, Zou X. Pantoprazole inhibits human gastric adenocarcinoma SGC-7901 cells by downregulating the expression of pyruvate kinase M2. Oncol Lett. 2016 Jan;11(1):717-722. doi: 10.3892/ol.2015.3912. Epub 2015 Nov 13. PMID: 26870273; PMCID: PMC4727057.
In vivo protocol:
1. Histing T, Stenger D, Scheuer C, Metzger W, Garcia P, Holstein JH, Klein M, Pohlemann T, Menger MD. Pantoprazole, a proton pump inhibitor, delays fracture healing in mice. Calcif Tissue Int. 2012 Jun;90(6):507-14. doi: 10.1007/s00223-012-9601-x. Epub 2012 Apr 24. PMID: 22527206. 2. Takeuchi K, Konaka A, Nishijima M, Kato S, Yasuhiro T. Effects of pantoprazole, a novel H+/K+-ATPase inhibitor, on duodenal ulcerogenic and healing responses in rats: a comparative study with omeprazole and lansoprazole. J Gastroenterol Hepatol. 1999 Mar;14(3):251-7. doi: 10.1046/j.1440-1746.1999.01843.x. PMID: 10197495.
1: Ragab MT, Abd El-Rahman MK, Ramadan NK, El-Ragehy NA, El-Zeany BA. Novel potentiometric application for the determination of pantoprazole sodium and itopride hydrochloride in their pure and combined dosage form. Talanta. 2015 Jun 1;138:28-35. doi: 10.1016/j.talanta.2015.01.045. Epub 2015 Feb 9. PubMed PMID: 25863367. 2: Ramadan NK, El-Ragehy NA, Ragab MT, El-Zeany BA. Simultaneous determination of a binary mixture of pantoprazole sodium and itopride hydrochloride by four spectrophotometric methods. Spectrochim Acta A Mol Biomol Spectrosc. 2015 Feb 25;137:463-70. doi: 10.1016/j.saa.2014.09.003. Epub 2014 Sep 10. PubMed PMID: 25238185. 3: Biju PG, Gubrij I, Garg S, Gupta PK, Hauer-Jensen M, Burnett AF. Radiation lethality potentiation in total body irradiated mice by a commonly prescribed proton pump inhibitor, Pantoprazole sodium. Int J Radiat Biol. 2014 Jul;90(7):554-9. doi: 10.3109/09553002.2014.905727. PubMed PMID: 24646079; PubMed Central PMCID: PMC4378842. 4: Naharcý MI, Cintosun U, Ozturk A, Bozoglu E, Doruk H. Pantoprazole sodium-induced hyponatremia in a frail elderly adult. J Am Geriatr Soc. 2014 Apr;62(4):787-8. doi: 10.1111/jgs.12767. PubMed PMID: 24731036. 5: Bhatt NM, Chavada VD, Sanyal M, Shrivastav PS. Manipulating ratio spectra for the spectrophotometric analysis of diclofenac sodium and pantoprazole sodium in laboratory mixtures and tablet formulation. ScientificWorldJournal. 2014 Feb 18;2014:495739. doi: 10.1155/2014/495739. eCollection 2014. PubMed PMID: 24701171; PubMed Central PMCID: PMC3948650. 6: Kamdi SP, Palkar PJ. Bioequivalence Study of Pantoprazole Sodium-HPBCD and Conventional Pantoprazole Sodium Enteric-Coated Tablet Formulations. ISRN Pharmacol. 2013;2013:347457. doi: 10.1155/2013/347457. Epub 2013 Feb 7. PubMed PMID: 23476803; PubMed Central PMCID: PMC3582054. 7: Dhurke R, Kushwaha I, Desai BG. Improvement in photostability of pantoprazole sodium by microencapsulation. PDA J Pharm Sci Technol. 2013 Jan-Feb;67(1):43-52. doi: 10.5731/pdajpst.2013.00901. PubMed PMID: 23385563. 8: Donnelly RF. Stability of pantoprazole sodium in glass vials, polyvinyl chloride minibags, and polypropylene syringes. Can J Hosp Pharm. 2011 May;64(3):192-8. PubMed PMID: 22479054; PubMed Central PMCID: PMC3130754. 9: Mostafa HF, Ibrahim MA, Mahrous GM, Sakr A. Assessment of the pharmaceutical quality of marketed enteric coated pantoprazole sodium sesquihydrate products. Saudi Pharm J. 2011 Apr;19(2):123-7. doi: 10.1016/j.jsps.2011.01.001. Epub 2011 Jan 22. PubMed PMID: 23960750; PubMed Central PMCID: PMC3744956. 10: Hein J. Comparison of the efficacy and safety of pantoprazole magnesium and pantoprazole sodium in the treatment of gastro-oesophageal reflux disease: a randomized, double-blind, controlled, multicentre trial. Clin Drug Investig. 2011;31(9):655-64. doi: 10.2165/11590270-000000000-00000. PubMed PMID: 21819161. 11: Chen MM, Wang CR, Jin Y. [Preparation of pantoprazole sodium enteric-coated pellets-type tablets]. Yao Xue Xue Bao. 2011 Jan;46(1):96-101. Chinese. PubMed PMID: 21465814. 12: Gupta NV, Shivakumar HG. Preparation and characterization of superporous hydrogels as pH-sensitive drug delivery system for Pantoprazole sodium. Curr Drug Deliv. 2009 Oct;6(5):505-10. PubMed PMID: 19863492. 13: Shao JG, Jiang W, Li KQ, Lu JR, Sun YY. Blood concentration of pantoprazole sodium is significantly high in hepatogenic peptic ulcer patients, especially those with a poor CYP2C19 metabolism. J Dig Dis. 2009 Feb;10(1):55-60. doi: 10.1111/j.1751-2980.2008.00363.x. PubMed PMID: 19236548. 14: Ding G, Tang A, Wang J, Cong R, Bao J. [Direct enantioseparation of pantoprazole sodium by high performance liquid chromatography on teicoplanin-bonded chiral stationary phase]. Se Pu. 2006 Jan;24(1):46-8. Chinese. PubMed PMID: 16827310. 15: Okazaki K, Mori S, Tahashi K. [Recent topics on important drugs for H. pylori eradication: Pantoprazole sodium]. Nihon Rinsho. 2005 Nov;63 Suppl 11:354-60. Review. Japanese. PubMed PMID: 16363559. 16: Ding G, Cong R, Wang J. [Direct enantiomeric separation of pantoprazole sodium by high performance liquid chromatography]. Se Pu. 2004 May;22(3):241-3. Chinese. PubMed PMID: 15712907. 17: Salama F, El-Abasawy N, Abdel Razeq SA, Ismail MM, Fouad MM. Validation of the spectrophotometric determination of omeprazole and pantoprazole sodium via their metal chelates. J Pharm Biomed Anal. 2003 Oct 15;33(3):411-21. PubMed PMID: 14550860. 18: Reddy GM, Bhaskar BV, Reddy PP, Ashok S, Sudhakar P, Babu JM, Vyas K, Mukkanti K. Structural identification and characterization of potential impurities of pantoprazole sodium. J Pharm Biomed Anal. 2007 Oct 18;45(2):201-10. Epub 2007 Jun 2. PubMed PMID: 17629653. 19: El-Sherif ZA, Mohamed AO, El-Bardicy MG, El-Tarras MF. Reversed-phase high performance liquid chromatographic method for the determination of lansoprazole, omeprazole and pantoprazole sodium sesquihydrate in presence of their Acid-induced degradation products. Chem Pharm Bull (Tokyo). 2006 Jun;54(6):814-8. PubMed PMID: 16755049. 20: Zupancic V, Ograjsek N, Kotar-Jordan B, Vrecer F. Physical characterization of pantoprazole sodium hydrates. Int J Pharm. 2005 Mar 3;291(1-2):59-68. Epub 2004 Dec 29. PubMed PMID: 15707732.